Strategic application of radiotherapy for hepatocellular carcinoma by �꽦吏꾩떎 & 理쒖꽌�씗
pISSN 2287-2728      
eISSN 2287-285X
https://doi.org/10.3350/cmh.2017.0073
Clinical and Molecular Hepatology 2018;24:114-134Review
Corresponding author : Jinsil Seong
Department of Radiation Oncology, Yonsei Cancer Center, Yonsei 
University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 
03722, Korea
Tel: +82-2-2228-8111, Fax: +82-2-2227-7823 
Email: jsseong@yuhs.ac
https://orcid.org/0000-0003-1794-5951
Abbreviations: 
BCLC, Barcelona Clinic Liver Cancer; CPT, Charged particle therapy; CR, complete 
response; CBCT, cone-beam CT; EASL-EORTC, European Association for the 
Study of the Liver and European Organization for Research and Treatment of 
Cancer; EBRT, external beam radiotherapy; FFLP, freedom from local progression; 
Gy, Gray; GyE, Gray-equivalent; HCC, hepatocellular carcinoma; IGRT, Image-
guided radiotherapy; IMRT, Intensity-modulated radiotherapy; LET, linear energy 
transfer; mUICC, modified Union for International Cancer Control; MLC, multileaf 
collimator; NCCN, National Comprehensive Cancer Network; OS, overall survival; 
PR, partial response; PVTT, portal vein tumor thrombosis; PFS, progression-free 
survival; PBT, proton beam therapy; RILD, radiation-induced liver disease; RFA, 
radiofrequency ablation; RT, radiotherapy; SBRT, stereotactic body radiotherapy; 
3D-CRT, three-dimensional conformal radiotherapy; TACE, transarterial 
chemoembolization Received : Nov. 30, 2017 /  Accepted : Dec. 6, 2017
INTRODUCTION 
Traditionally, the role of radiotherapy (RT) for hepatocellular car-
cinoma (HCC) has been limited due to the relatively low liver tol-
erance to radiation, although many are not candidates for curative 
treatment or not adequately treated with transarterial chemoem-
bolization (TACE), radiofrequency ablation (RFA), or sorafenib. Well-
known Barcelona Clinic Liver Cancer (BCLC) guidelines for HCC 
did not recommend RT as a primary treatment option for all stages 
of HCC. In clinical guidelines of the European Association for the 
Study of the Liver and European Organization for Research and 
Treatment of Cancer (EASL-EORTC), use of external beam radio-
therapy (EBRT) was also limited due to the possibility of radiation-
induced liver disease (RILD), and reasons for the benefits of three-
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With increasing clinical use, radiotherapy (RT) has been considered reliable and effective method for hepatocellular 
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dimensional conformal radiotherapy (3D-CRT) have only been 
shown in uncontrolled studies. 
However, with increasing clinical use, RT has been considered 
reliable and effective for HCC treatment, depending on each stage. 
In addition, further development of modern RT technologies, includ-
ing intensity-modulated radiotherapy (IMRT), image-guided radio-
therapy (IGRT), and stereotactic body radiotherapy (SBRT), have 
expanded the indication of RT. In comparison to 3D-CRT, distinc-
tions of IMRT include inverse treatment planning process and use 
of a large number of treatment fields or subfields, which provide 
high precision and exquisitely conformal dose distribution. Further-
more, the addition of multileaf collimator (MLC) enables non-uni-
form intensity profiles in various ways.
The role of RT is documented in several clinical guidelines. Ac-
cording to the most recent National Comprehensive Cancer Net-
work (NCCN) guideline1, EBRT is suggested as a locoregional treat-
ment option for patients with unresectable HCC who are ineligible 
for transplantation, inoperable due to comorbidities, or those who 
have a local disease with/without minimal extrahepatic disease, 
with evidence level of 2B. Locoregional therapy, including EBRT, is 
also suggested as a treatment option for patients who have oper-
able tumors, although resection is the preferred treatment. The 
guideline also mentions feasibility of modern RT and indications 
for SBRT. Korean Liver Cancer Study Group (KLCSG) has published 
the first comprehensive guidelines in 2003 with details regarding 
RT indication, and these guidelines have been updated recently in 
2014.2 The KLCSG guideline provides multiple treatment sugges-
tions for each stage based on the modified Union for International 
Cancer Control (mUICC) staging system, and lists the best options 
and alternatives. Based on recent perspectives, KLCSG is currently 
revising its 2014 guideline and discussing ways to further refine 
and expand the role of RT.
In this review, we describe the technical aspects of modern RT 
techniques for HCC along with their clinical applications in HCC, 
mainly according to the mUICC staging system. Furthermore, we 
introduce recent trends of RT, such as particle therapy.
MODERN RADIOTHERAPY TECHNIQUES 
Intensity-modulated radiotherapy (IMRT)  
Development of RT mainly focuses on improving two factors: ac-
curacy and precision. Accuracy of RT implies that radiation can be 
delivered to the correct location each time, despite various uncer-
tainties between the time of radiation treatment planning and the 
time of actual treatment. Precision of RT means the ability to con-
trol distribution of radiation to make sure that prescribed dose is 
administered exactly to tumor site, and that radiation is not deliv-
ered to surrounding normal tissues.
In the past, it was possible to perform treatment using two-di-
mensional fluoroscopic imaging plan and estimate radiation distri-
bution in only one direction (“2D-RT”). Based on the development 
of computer engineering and radiology, computerized tomography 
(CT) images were used in planning simulation, while considering 
the three-dimensional positional relationship between tumor and 
surrounding normal tissues, in addition to more conformal treat-
ments (“3D-CRT”). IMRT is the most advanced 3D-conformal treat-
ment technique. It modulates the intensity of radiation delivered in 
each treatment direction, and selectively delivers the desired dose 
of radiation only to the tumor site while minimizing the amount of 
radiation entering normal tissue around tumor (Fig. 1). The core of 
this treatment technique is the so-called “inverse treatment plan-
ning,” in which the physician sets the ideal dose of targets and nor-
mal organs, and relative importance for tumor and surrounding 
organs in advance. Then, the machine computes and determines 
numbers and angles of beams. In the past, physicians performed 
target contouring and determined numbers and angles of beams, 
and then the machine performed RT (“Forward planning”) (Fig. 2).
Control of respiratory motion during radiation 
delivery
Another critical issue in RT for HCC is the control of respiratory 
motion, as the liver moves in a considerable range during respira-
Figure 1. Comparison of treatment volumes by various radiotherapy RT 
technology involving 2D radiotherapy, 3D conformal radiotherapy (3D-
CRT), and intensity modulated radiotherapy (IMRT). IMRT is the most ad-
vanced 3D-conformal treatment technology. It modulates the intensity 
of radiation delivered in each treatment direction, and selectively delivers 
the desired dose of radiation only to the tumor site, while minimizing the 
amount of radiation entering sensitive normal organs around the tumor 
with high precision. 
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tion. There are several ways to treat a moving tumor to ensure the 
tumor receives intended dose while reducing the dose to sur-
rounding normal tissue. The strategies can be classified into mo-
tion-encompassing, breath-hold, forced shallow breathing with 
abdominal compression, respiratory gating, and real-time tumor 
tracking.
Motion-encompassing method refers to the covering of all pos-
sible positions of moving tumor through the entire breathing cycle 
using 4D-CT images. Subsequently, a large volume of normal tis-
sue may be irradiated. Breath-hold method refers to letting the pa-
tient hold his or her breaths for a few seconds under deep inspira-
tion, and then deliver radiation only when the liver is in a certain 
position. Forced shallow breathing is using a particular external 
device, such as an abdominal compressor, to allow the patient to 
breathe shallow during radiation therapy. Although breath-hold 
and forced shallow breathing might result in patient discomfort or 
inconvenience during treatment, it can reduce respiratory motion 
for liver tumors and enhance accuracy. 
Currently, respiratory gating and real-time tumor tracking are 
considered the most advanced techniques. Respiratory gating 
method involves turning on the radiation beam only during a spe-
cific respiratory cycle, after accurately grasping the position of tu-
mor according to the patient’s respiratory cycle in advance, using 
4D-CT images.
Real-time tracking method refers to tracking the movement of 
tumor along respiratory cycle using the surrogate on abdominal 
surface or internal fiducial marker, and then delivering radiation 
by following tumor inside the body. No respiratory control and 
abdominal compression are needed. This gating method using an 
external breathing signal is natural, noninvasive, and radiation-
free; however, potential error might be that the signal does not 
accurately correlate with internal target position. On the other 
hand, the use of internal fiducial markers is an invasive method; 
however, it can improve the accuracy of treatment. Currently, one 
of the machines that are capable of tumor tracking is the Cy-
berKnife system. Clinical feasibility of CyberKnife system has been 
demonstrated in several studies, especially SBRT papers. Cy-
berKnife SBRT has been proven to be a safe and effective nonin-
vasive treatment for HCC.3-7 CyberKnife system consists of a pair 
of fluoroscopes in the ceiling coupled to a small X-band linear ac-
celerator mounted on robotic arm, which can move according to 
the movement of inserted fiducial markers. Patients are encour-
aged to undergo implantation of three or more fiducial markers in 
the liver parenchyma around the perimeter of tumor before treat-
ment, which would serve as radiographic landmarks for respirato-
ry synchrony system and image guidance technique.
Image-guided radiotherapy (IGRT)
IGRT is defined as RT that utilizes imaging to maximize accuracy 
throughout the entire treatment process, including precise target-
ing and normal tissue representation, radiation delivery, and adap-
tive plans for anatomic and biological changes over time for the 
patient. Of these, accurate target delineation, target relocalization 
Figure 2. Concept of inverse planning of intensity modulated radiotherapy (IMRT). In the past, physicians performed target contouring and deter-
mined numbers and angles of the beams, and then the machine performed radiotherapy (“forward planning”). The core of IMRT technique is the so-
called “inverse planning,” in which the physician sets ideal dose of targets and normal organs, and relative importance for the tumor and surrounding 
organs in advance. Then, the machine computes and determines numbers and angles of the beams. 
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to allow proper patient repositioning, and respiratory motion man-
agement have been the most challenging for patients with HCC, 
mainly due to the uncertain movement of the liver.
An essential feature of IGRT is that it allows image guidance ther-
apy through in-room images obtained during radiation delivery 
(Fig. 3). This leads to more precise treatment by reducing inter- and 
intra-fractional errors that result from daily changes in the liver to 
bones, breathing motion, and variation in shape and position of 
neighboring organs. Physicians can reduce target margins and 
spare additional normal tissue dose using 2D or 3D image guid-
ance techniques (helical megavoltage CT, kilovoltage cone-beam 
CT (CBCT), and MV CBCT), compared to in-room laser beams and 
skin marks (Fig. 3). Degree of error is evaluated by comparing ref-
erence images to in-room images. If the error is beyond allowable 
range and physicians see a need for adaptive planning, they 
should retake planning CT and restart treatment after new RT 
Figure 4. Workflow of image-guided radiotherapy (IGRT). An essential feature of IGRT is that it allows image guidance therapy through in-room imag-
es obtained during radiation delivery. Physicians can reduce target margins and spare additional normal tissue dose using 2D or 3D image guidance 
techniques (helical megavoltage CT (MVCT), kilovoltage cone-beam CT (CBCT), and MV CBCT), compared to in-room laser beams and skin marks. De-
gree of error is evaluated by comparing reference images with in-room images at every treatment time. If the error is beyond the allowable range and 
physicians sees a need for adaptive planning, they should retake a planning CT and restart treatment after new RT planning.
Figure 3. Illustration of image-guided radiotherapy (IGRT) with daily setup using three-dimensional volumetric imaging modality. Matching between 
“reference images” using three-dimensional reconstruction of planning computed tomography images and in-room cone-beam computed tomogra-
phy images are performed on each day of treatment.
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planning (Fig. 4).
RADIOTHERAPY FOR EARLY STAGE (mUICC 
STAGE I/II) HCC 
Curative therapies can improve survival in early-stage HCC pa-
tients. Resection, percutaneous ethanol injection (PEI), and RFA 
have been considered valid local ablative treatments. However, 
when the effect is limited for reasons of primary tumor location 
(e.g., near the liver dome, or major vessels), RT may be considered 
as an alternative. Also, RT may be a feasible alternative for those 
who are inoperable or refuse surgery. 
SBRT for early stage HCC
Local high-dose RT, including SBRT, can be an appropriate alter-
native definitive or salvage treatment. In several prospective8-17 
(Table 1) or retrospective3,4,18-29 (Table 2) papers, SBRT has been re-
ported as a very effective, safe, and noninvasive treatment modal-
ity in primarily diagnosed or recurrent cases when size and position 
are acceptable. Honda Y, et al. demonstrated that SBRT combined 
with TACE is a safe and effective modality for locoregional treat-
ment of small solitary primary HCC, with a 96% of high complete 
response (CR) rate.22 Even for huge HCC ≥10 cm, SBRT could be a 
safe and effective treatment option. Jang WI, et al. suggested that 
there was a positive linear relationship between SBRT dose and 
2-yr local control, overall survival (OS) rates, which were highest 
at >54 Gy.24 Sometimes, SBRT was also used for portal vein tumor 
thrombosis (PVTT) and/or inferior vena cava tumor thrombosis23,27, 
BCLC stage C HCC27, or huge HCC ≥10 cm28,29, with acceptable re-
sponse rates and survival outcomes. Wahl DR, et al. compared out-
comes of patients with inoperable, nonmetastatic HCCs who un-
derwent SBRT or RFA.30 For tumors <2 cm, there was no significant 
difference between RFA and SBRT in freedom from local progres-
sion (FFLP) (HR, 2.50; 95% CI, 0.72 to 8.67; P=0.15); however, for 
tumors ≥2 cm, RFA was associated with significantly worse FFLP 
(HR, 3.35; 95% CI, 1.17 to 9.62, P=0.025).
Radiotherapy as bridging treatment before liver 
transplantation
O’Connor JK, et al. reported that SBRT could be used as effective 
bridging treatment before liver transplantation.31 In a recent study 
from Toronto General Hospital 32, 379 patients who underwent liv-
er transplantation after SBRT (n=36), TACE (n=99), or RFA (n=244) 
were compared, to evaluate the safety and efficacy of bridging 
treatments. Drop-out rate and postoperative complication rates 
were similar between groups. The 3-year survival rate from time of 
transplant was 75% in SBRT group, 75% in TACE group, and 81% 
in RFA group, which were not significantly different. This showed 
that SBRT might be as effective and safe as TACE or RFA, when 
used to maintain candidacy of patients with HCC who are on the 
wait-list for a transplant for the first time.
RADIOTHERAPY FOR INTERMEDIATE STAGE 
(mUICC STAGE II/III) HCC 
In general, intermediate stage HCC is considered primarily for 
TACE. However, the effects of TACE may be limited if there is vascu-
lar shunting, recanalization around the tumor capsule, or develop-
ment of multiple feeding vessels. TACE is contraindicated in patients 
with PVTT or inferior vena cava invasion, as it has potential risk of 
ischemic liver damage.33 In addition, complete or massive necrosis 
is seldom observed following TACE, when the tumor is >5 cm.34,35 
In HCCs that either showed incomplete response after TACE or 
were unsuitable for TACE, RT can be useful as a complementary 
modality.36-39 
Radiotherapy for unresectable HCC after incomplete 
TACE
In many prospective40-45 or retrospective36,39,46-49 papers, large un-
resectable HCCs were well treated with TACE followed by EBRT, and 
objective response rates (complete and partial responses) were 
achieved in about 63-76% of cases with 72-82% of 1-year surviv-
al rate, which is significantly higher compared to patients without 
EBRT (Table 3). A recent prospective phase II multicenter study45 
investigated the efficacy and toxicity of RT following incomplete 
TACE in unresectable HCCs. Here, patients with unresectable HCC 
who had viable tumor after TACE of no more than three courses 
were eligible, and median 54 Gy of 3D-CRT was delivered. Best 
objective infield response rate was achieved in 84% of patients, 
with 23% of CR rates and 61% of partial response (PR) rates with-
in 12 weeks post-RT. The 2-year in-field progression-free survival 
(PFS), overall PFS, and OS rates were 45%, 29%, and 61%, respec-
tively. These findings demonstrate that early application of 3D-CRT 
can be a promising option in multimodal approaches for patients 
with incomplete necrosis after TACE. Meng MB, et al. performed 
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meta-analysis from five randomized controlled trials and 12 non-
randomized controlled clinical trials, which compared TACE+RT 
group and TACE alone group.50 TACE+RT significantly improved 
survival rates and CR rates (OR, 2.58; 95% CI 1.64–4.06; P=0.0001). 
Rates of adverse events were not significantly different, except for 
elevation of total bilirubin level. Other meta-analyses51,52 also pre-
sented similarly favorable outcomes with TACE+RT compared to 
using TACE alone.
RADIOTHERAPY FOR ADVANCED STAGE 
(mUICC STAGE III/IV) HCC 
Radiotherapy for unresectable HCC with PVTT
For patients who are unsuitable for TACE due to PVTT, value of 
RT has been especially noticeable in several prospective44,53-57 and 
retrospective studies.38,58-67 About 31% to 83% of objective re-
sponse rates and median OS of 7 months to 34 months in respond-
ers have been reported 37,59,61,67,68(Table 4). According to Korea’s 
long-term follow-up data,59 authors reported clinical outcomes of 
patients who underwent RT for HCC with PVTT. With radiation 
volume including PVTT (±whole HCC), median survival time was 
10.6 months, and 1-year survival rate was 43%. Furthermore, 
3.6% of patients achieved CR and 24.3% of patients achieved 
PR, with 10% of grade 3-4 hepatic toxicity and 4% of gastroduo-
denal complications. TACE plus RT achieved significant survival ad-
vantage in HCC with PVTT than using TACE alone, according to pro-
pensity score matching.69 Median survival time was 10.9 versus 4.1 
months (P<0.001) in all patients, 12.5 versus 4.4 months (P=0.002) 
in patients with PVTT involving the right/left portal vein, and 8.9 
versus 4.0 months (P<0.001) in patients with PVTT involving the 
main portal vein trunk. Based on another paper,62 TACE+RT showed 
longer OS in selected patients with locally advanced HCC in BCLC 
stage C who had macrovascular invasion in 96% of cases and re-
ceived RT to vascular invasions, compared to sorafenib event after 
propensity score matching. Tang QH, et al.61 also compared the 
outcomes of surgical resection plus 3D-CRT to tumor and PVTT with 
resection alone. There was a median survival advantage of 2.3 
months (P=0.03), and 1-year survival rate was 52%. Stereotactic 
ablative radiotherapy (SABR) (median 40 Gy in 4-5 fractions) us-
ing CyberKnife was also suggested as a feasible treatment op-
tion.70 In a multicenter retrospective study in Korea,67 outcomes of 
985 patients who received RT for PVTT (±whole HCC) were ana-
lyzed, and response rate of PVTT was reported as 52%. Respond-
ers had significantly more prolonged survival (15 vs. 10 months) 
and equivalent RT dose >45 Gy when given in combination with other 
treatments, and provided significantly better PVTT control and OS.
Recently, meta-analysis results of eight clinical studies regarding 
this subject were published in China.71 TACE+RT significantly im-
proved objective response rate (OR, 4.22; 95% CI, 3.07–5.80; 
P<0.001) of PVTT and OS (HR, 0.69; 95% CI, 0.57–0.83; P=0.001), 
compared to TACE alone, although incidence of grade 3 or 4 leu-
kopenia and thrombocytopenia was significantly higher.
Radiotherapy for huge HCC
RT can be very challenging to perform in some cases of very large 
unresectable HCCs. Although TACE has been frequently used in 
treatment of unresectable HCC, its limitation has also been well 
known, especially in large tumors, particularly regarding compli-
cated blood supply and high incidence of residual viable tumor even 
after repeated treatment. Although surgical resection could also 
be tried in some cases, its indication is very limited. Shim SJ, et al. 
showed that TACE+RT offered more significant benefit than TACE 
alone when tumor size was larger.37 According to the specific tu-
mor size, 2-year survival rates in TACE+RT and TACE groups were 
63% vs. 42% in 5–7 cm (P=0.22), 50% vs. 0% in 8–10 cm (P=0.03), 
and 17% vs. 0% in larger than 10 cm (P=0.002), respectively. In ad-
dition, Kim KH, et al. tried to find the most optimal treatment for 
huge HCCs ≥10 cm in patients who received various treatments at 
the same single institution.72 Median OS was longer in TACE+RT 
group (15.3 months) and concurrent chemoradiotherapy (CCRT) 
group (12.8 months), compared to TACE alone group (7.5 months) 
and hepatic arterial infusion chemotherapy (HAIC) alone group 
(8.2 months); this indicated that huge unresectable HCCs treated 
with RT, either as CCRT or in combination with TACE, showed ex-
cellent intrahepatic control and prolonged survival.
RT for HCC with multiple intrahepatic metastases
The role of local RT is more uncertain for HCC with multiple intra-
hepatic metastases. In one retrospective study73, local RT to the 
main tumor was most beneficial with well-controlled intrahepatic 
tumors out of RT field. Patients with viable intrahepatic tumors out 
of RT field showed worse survival. Survival was similar when all le-
sions were covered by RT field, or lesions out of RT field were con-
trolled by TACE. In a more recent study57, TACE for intrahepatic me-
tastases and localized CCRT were given to HCCs with portal vein 
invasion and intrahepatic metastasis. Objective response rate was 
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32.1%, and median PFS and OS were 4.5 months and 9.8 months, 
respectively. Incidence of grade 3–4 toxicity was low, manage-
able, and predictable, although two patients dropped out due to 
grade 3 nausea and vomiting.
Concurrent chemoradiotherapy for advanced stage 
HCC
Several studies have indicated that hepatic arterial infusion con-
current chemoradiation (HAICCRT) may be a feasible and effective 
alternative for unresectable liver-confined HCC with vascular inva-
sion. The purpose of using HAIC in CCRT was to enhance local ra-
dio-therapeutic effect and to reduce intrahepatic HCC spread. 
One pilot clinical study reported that CCRT improved response 
rates and survival for locally advanced HCC with portal vein inva-
sion.54 One month after localized CCRT, objective response was ob-
served in 45% of patients, and 3-year survival rate was 24% which 
was significantly better compared to non-responders. More recent-
ly, the same institution showed treatment outcomes of 30 HCCs 
with portal vein invasion and intrahepatic metastasis.57 After TACE 
for intrahepatic metastasis, localized CCRT (45 Gy in 25 fractions) 
was used to treat the main HCC with PVT. Objective response rate 
was about 30% and median OS was 9.8 months, without any se-
vere adverse events. Review of nationwide multi-center HCC co-
hort (stage III-IV, CP-A) showed that patients who underwent de-
finitive CCRT as initial treatment showed significantly better OS 
(median 11.4 versus 6.6 months, P=0.02) than matched patients 
who did not receive CCRT.74 CCRT followed by HAIC in locally ad-
vanced HCC could even increase resectability by down-staging tu-
mors and increasing functional residual liver volume, and 5-year 
OS was significantly increased to 50% (versus 10%).75,76 In addi-
tion, EBRT can significantly relieve symptoms that are caused by 
locally advanced HCC or metastatic tumors, and even a prolonga-
tion of survival period can be expected.77,78
DOSE CONSTRAINTS
Development of improved treatment planning and dose delivery 
methods, such as 3D-CRT and IMRT, provided a mechanism not only 
to target hepatic lesions while sparing uninvolved hepatic paren-
chyma but also to precisely measure radiation dose delivered to 
both tumor volume and surrounding normal tissue. Despite tech-
nical advances, RILD still remains to be a side effect that presents 
significant concerns when planning RT for HCC.
RILD is a clinical syndrome of anicteric hepatomegaly, ascites, 
and elevated liver enzymes (particularly serum alkaline phospha-
tase) that occurs typically 2 weeks to 4 months after completion 
of hepatic irradiation. Tolerance of the whole liver to radiation is 
low, and RILD is seen in 5–10% of patients treated with 30–35 
Gy to the whole liver, based on several Radiation Therapy Oncolo-
gy Group (RTOG) studies in the 1970’s and 1980’s. For this reason, 
radiation has traditionally played a limited role in the treatment of 
liver tumors. However, treatment of liver parts using higher radia-
tion doses is possible without adverse effects, as long as an ade-
quate volume of normal liver is saved. 
While the Emami report established baseline liver tolerance 
doses based on literature reports of toxicity,79 later studies provid-
ed more detailed assessment and guidelines regarding the risk of 
hepatotoxicity for given RT doses. At the University of Michigan,80 
dose-volume tolerance for RILD using the Lyman-Kutcher-Burman 
(LKB) normal tissue complication probability (NTCP) model was de-
scribed. They demonstrated that the liver exhibits a large volume 
effect for RILD, suggesting that the mean liver dose may be useful 
in ranking radiation plans. No cases of RILD were observed when 
the mean liver dose was <31 Gy. Furthermore, multivariate analy-
sis demonstrated that, in addition to NTCP and the mean liver 
dose, a primary hepatobiliary cancer diagnosis (vs. liver metasta-
ses), bromodeoxyuridine hepatic artery chemotherapy (vs. fluoro-
deoxyuridine chemotherapy), and male gender were associated 
with RILD. In a preclinical study81 that treated rat cirrhosis model 
with mildly impaired liver function, combined treatment of partial 
RT plus 5-FU resulted in a significantly high incidence of lethal liv-
er injury. According to Dawson LA’s review paper,82 if the effective 
liver volume irradiated is less than 25%, very high RT doses (>100 
Gy) may be delivered with little risk of liver toxicity, as long as the 
liver function is proper. In addition, RT tolerance of the liver is re-
duced in patients with primary liver cancer versus metastases. The 
mean liver doses associated with 5% risk of classic RILD for pri-
mary and metastatic liver cancer are 28 Gy and 32 Gy, respective-
ly, in 2 Gy per fraction.
According to recent papers,83,84 there are several dose-volumetric 
parameters related to the risk of RILD, which are also included in 
the 2014 KLCSG guidelines. Tumor volume must be limited to 
≤70% of the total liver volume, and liver volume receiving ≥30 Gy 
must be constrained to ≤60% of total liver volume on dose-volume 
histograms for 3D-RT planning. For SBRT, normal liver volume re-
ceiving a total dose of <15 Gy must be ≥700 mL, or the mean nor-
mal liver dose (liver minus gross tumor volume) must be limited to 
<28 Gy in 2-Gy fractions. Although additional studies for liver toler-
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ance to radiation are still needed, several institutions have similarly 
applied dose–volume histogram parameter-based RT guidelines. 
CHARGED PARTICLE THERAPY
Charged particle therapy (CPT), such as proton and carbon ion 
therapy, is a form of radiotherapy with superior depth dose distribu-
tion compared to photon radiotherapy. This superiority in depth 
dose distribution is attained by the energy-dependent specific range 
of charged particles within the tissues and the Bragg peak, which 
is the sharp peak of energy deposit just before stopping the parti-
cle. Consequently, tumors can be treated more efficiently with less 
toxicity by charged particles than by photons on theoretical grounds, 
even in the cirrhotic liver with limited hepatic functional reserve. 
Some retrospective and prospective studies have reported encour-
aging outcomes with proton or carbon beam therapy in patients 
with HCC. Local control rates were 88%-98% at 2-5 years, with 
very low incidence of severe toxicity. 
Proton beam therapy
At the University of Tsukuba, long-term results of proton beam 
therapy (PBT) for HCCs were reported.85-88 A total dose of 77.0 
gray-equivalent (GyE) in 35 fractions was administered for tumors 
located within 2 cm of a digestive organ, 72.6 GyE in 22 fractions 
was administered for tumors located within 2 cm of the porta 
hepatis, and 66.0 GyE in 10 fractions was administered for periph-
eral tumors located more than 2 cm from both GI tract and porta 
hepatis. The 5-year survival was 23.5%, and local control rate was 
86.9%. For a patient subgroup having BCLC stage 0/A HCCs, 
5-year local control, PFS, and OS rates were much higher (94%, 
28%, and 69%). Otherwise, there were very few acute reactions 
to treatment, in addition to a few grade 2 or more severe sequel-
ae. So far, the largest prospective study of PBT for HCC was re-
ported by the Loma Linda University Medical Center.89,90 After 63 
GyE in 15 fractions of PBT, 20% had experienced local treatment 
failure, and median PFS was 36 months. No acute toxicity that re-
quired treatment interruption was found; however, five cases of 
grade 2 gastrointestinal bleeding or ulceration near the irradiated 
area were observed in patients who were treated in earlier period. 
In another phase II study of MGH,91,92 67.5 GyE and 58.05 GyE in 
15 fractions for peripheral and central tumors were delivered, and 
94% of favorable 2-year local control rate was reported. No local 
recurrence was reported with ≥60 GyE, and median PFS and OS 
were 13.9 months and 49.9 months, respectively. In other pro-
spective studies,93-95 PBT showed about 95% of 2-year local con-
trol rates and 63-66% of 2-yr OS rates (Table 5). In a recent inter-
im analysis of prospective randomized clinical trial comparing PBT 
and TACE96, 2-year local control and PFS rates were higher with PBT 
(88% vs. 45%, 48% vs. 31%), although they were not significantly 
different. The total number of hospitalization days was signifi-
cantly shorter in patients with PBT (24 vs. 166 days, P<0.001). 
Pathologic complete response was achieved in 10% of TACE 
group and 25% of PBT group, who underwent liver transplantation 
after treatment. There was a trend toward improved 2-year local 
control (88% vs. 45%, P=0.06) and PFS (48% vs. 31%, P=0.06) fa-
voring PBT. 
Excellent local tumor control was reported, even in tumors with 
portal vein invasion (Table 5).97-99 Sugahara S, et al.98 demonstrat-
ed that 2-year PFS and OS rates were 91% and 33-57% after PBT 
for HCC with PVTT, without treatment-related severe complica-
tions. Kim, et al.93 also treated HCC with PVT, and local recurrence 
was noted in only 12% of patients during follow-up period, with-
out local recurrence or severe gastrointestinal toxicity. In addition, 
proper local control rates can be expected for HCC patients with 
large tumors (87% at 2 years for tumors >10 cm) or portal tumors 
(86% at 3 years), as well as for elderly patients (100% at 3 years 
for patients aged ≥80 years).100-103 Even for recurrent tumors after 
PBT, repeated PBT can be safely delivered with an excellent local 
control rate of 87.8% at 5 years.104
With concerns about gastrointestinal toxicities and hepatic in-
sufficiencies, Kawashima M, et al.105 analyzed dose-volume histo-
gram of 60 patients with HCC who were treated by PBT, and re-
ported ICG R15 and V30 as useful predictors. According to the 
location of tumor, a risk-adapted simultaneous integrated boost 
technique could be utilized to avoid gastrointestinal toxicities. When 
PTV overlaps the planning organ at risk volume (PRV) of gastroin-
testinal tract, 50–60 GyE in 10 fractions was prescribed to PTV mi-
nus the overlapping volumes, whereas the dose to overlapping 
volumes was restricted to 30 GyE in 10 fractions.106 Mizumoto M, et 
al.86 also suggested risk-adapted selection scheme dose fraction-
ation schedules. They adopted a small fraction dose schedule of 77 
GyE in 35 fractions with gastrointestinal tract avoidance as far as 
possible, after 40–50 GyE for tumors proximal to the alimentary 
tract with reduced risk of gastrointestinal toxicities.
Carbon ion beam therapy
Although it is expected that the biological benefits of high rela-
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tive biological effectiveness (RBE) and high linear energy trans-
fer (LET) of carbon ion beam would offer better treatment effi-
cacy than photon or PBT, clinical experience for carbon ion 
beam is not yet extensive.
The first clinical result of carbon ion therapy for HCC was 
published by the NIRS in 2004.107 In 24 patients who were en-
rolled in this study and received 49.5 GyE-79.5 GyE in 15 frac-
tions, 3-year local control and OS rates were 81% and 50%, 
respectively. The OS rates of patients who had not received 
previous treatment for HCC were significantly higher than 
those who did. In particular, there was no local recurrence in 
patients receiving more than 72 GyE, and severe adverse 
events were not reported at any dose level. To date, NIRS re-
searchers have conducted several other clinical trials for HCC 
with short-course irradiation regimens. A four-fraction regi-
men, with a total dose of 52.8 GyE, also yielded a high local 
control rate of 94% at 3 years.108 Although local control rates 
for porta hepatis lesions were slightly worse than those for 
non-porta hepatis lesions, the difference was not statistically 
significant (88 vs. 96%, P=0.306).109 Two-fraction regimens 
are now being adopted with minor adverse events only,110 and 
follow-up clinical data is not yet available. Other hypofraction-
ated regimens with dose escalation have been also studied, 
and mature data will be reported in the near future.
Komatsu S, et al. compared the clinical outcomes of PBT (278 
tumors) to carbon ion therapy (108 tumors) in patients who were 
treated at the same institution.111 The 5-year local control rates 
for PBT and carbon ion were 90% and 93%, respectively. For 
tumors <5cm, local control rates were similar between two 
modalities (96% vs. 95%); however, the rates were slightly 
lower with PBT than carbon ion therapy for larger tumors 
(84% vs. 91% for tumors of 5-10cm; 43% vs. 80% for tumors 
>10cm). In meta-analysis of 70 non-comparative observational 
studies (73 cohorts; 53 with photon therapy, and 20 with 
CPT)112, the median radiation dose was higher in CPT cohorts 
compared to SBRT and conventional RT cohorts, while the me-
dian rate of patients with child-pugh A class was higher in CRT 
cohorts than in other cohorts. Additionally, median tumor size, 
rate of male, rate of patients with ECOG PS 0–1, or median 
HCC patients with tumor vascular thrombosis did not signifi-
cantly differ between groups. The OS, PFS, and local control 
rates were significantly higher for CPT than those for conven-
tional RT, while they were similar to SBRT in patients with 
HCC. Furthermore, high-grade acute and late toxicities were 
lower for CPT compared to conventional RT or SBRT. Ta
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So far, CPT generally showed better local control and survival 
rates than photon-based RT series, although a direct comparison 
is difficult due to differences in patient characteristics. Although 
facilities for CPT have been limited to this day, the use of CPT is 
anticipated to increase in the near future.
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